Balstilimab + evofosfamide + zalifrelimab for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Jan 2025: Trial started, NCT06782555
  2. 20 Jan 2025: Trial registered, NCT06782555

The trials

NCT06782555: A Study of Evofosfamide in Combination With Zalifrelimab and Balstilimab

State
Under way
Phase
Phase 1 and Phase 2
People
71 planned
Started
8 Jan 2025
Primary completion
Oct 2027
Arms
Castration-resistant prostate cancer, Pancreatic cancer, Human papilloma virus-negative squamous cell carcinoma of the head and neck
Results
None posted
  1. 8 Jan 2025: Trial started
  2. 20 Jan 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.